Showing results (31-40 of 104) with videos related to

Sort By:
Pageof 11
Fetal Diagnosis and Therapy|August 18, 2001
Pulmonary atresia with hypoplastic right ventricle. A clinical embryological studyR Fröber, T Kohoutek, C Kähler, et al.
Brain, Behavior, and Immunity|December 1, 1992
In vivo activation of circulating monocytes by exogenous growth hormone in manC J Wiedermann, N Reinisch, C Kähler, et al.
Zeitschrift Fur Geburtshilfe Und Neonatologie|December 1, 2001
[Nitroglycerin patch for tocolysis--a prospective randomized comparison with fenoterol by infusion]E Schleussner, S Richter, W Gross, et al.
Journal of the American Academy of Dermatology|April 29, 2014
Ipilimumab in patients with cancer and the management of dermatologic adverse eventsMario E Lacouture, Jedd D Wolchok, Gil Yosipovitch, et al.
International Journal of Molecular Medicine|December 29, 1998
Translocation trisomy dup(21q) and free trisomy 21 can be distinguished by interphase-FISHT Liehr, H Starke, V Beensen, et al.
Melanoma Management|August 29, 2025
Personalized therapies in advanced BRAFV600-mutated melanoma: review based on 3 case reports of the REMINISCENCE projectChristoffer Gebhardt, Dirk Debus, Peter Rohrer, et al.
Prenatal Diagnosis|December 11, 1999
Molecular cytogenetic characterization of a prenatally detected supernumerary minute marker chromosome 8H Starke, I Schreyer, C Kähler, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|July 5, 2016
Management of side effects of immune checkpoint blockade by anti-CTLA-4 and anti-PD-1 antibodies in metastatic melanomaKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|June 4, 2020
Side effect management during immune checkpoint blockade using CTLA-4 and PD-1 antibodies for metastatic melanoma - an updateKatharina C Kähler, Jessica C Hassel, Lucie Heinzerling, et al.
Pageof 11